Bright Minds Biosciences (DRUG) Depreciation & Amortization (CF) (2022 - 2026)

Bright Minds Biosciences has reported Depreciation & Amortization (CF) for 5 years, with the latest figure at $14439.0 in Q1 2026.

• For the quarter ending Q1 2026, Depreciation & Amortization (CF) fell 7.84% year-over-year to $14439.0; the trailing twelve-month figure through Mar 2026 stood at $52424.3 (down 10.17% YoY), and the FY2025 full-year result was $55855.0, up 3.87% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $14439.0, up from $14190.4 in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $49128.5 in Q3 2024, with the low at -$21851.6 in Q2 2024.
• Historically, Depreciation & Amortization (CF) has averaged $13661.8 across 5 years, with a median of $13462.7 in 2023.
• The largest YoY upside for Depreciation & Amortization (CF) was 263.64% in 2024 against a maximum downside of 262.05% in 2024.
• Bright Minds Biosciences' Depreciation & Amortization (CF) stood at $13343.2 in 2022, then retreated by 0.29% to $13304.6 in 2023, then climbed by 15.86% to $15414.4 in 2024, then decreased by 7.94% to $14190.4 in 2025, then rose by 1.75% to $14439.0 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $14439.0 (Q1 2026), $14190.4 (Q4 2025), and $12359.3 (Q3 2025), per Business Quant data.